Drug Profile


Alternative Names: M-PA01; PANDA; Pyramax; Pyronaridine/artesunate

Latest Information Update: 30 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medicines for Malaria Venture; Shin Poong Pharmaceutical
  • Class Antimalarials; Naphthyridines; Peroxides; Sesquiterpenes; Small molecules
  • Mechanism of Action Free radical stimulants; Hemozoin inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Malaria

Most Recent Events

  • 30 May 2017 Artesunate/pyronaridine is still at registration stage for Malaria in Cambodia and Vietnam (PO,tablet) (Medicines for Malaria Venture website, May 2017)
  • 30 May 2017 Registered for Malaria in Myanmar, Uganda, Nigeria, Niger, Mozambique, Mauritania, Mali, Guinea, Kenya, Gabon, Democratic Republic of the Congo, Congo, Ivory Coast, Chad, Central African Republic, Burkina Faso, and Benin (PO,tablet) before May 2017 (Medicines for Malaria Venture website, May 2017)
  • 23 Nov 2015 The European Medicines Agency recommends approval of pyronaridine/artesunate under Article 58 for Malaria (In children) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top